In the Sidra-LUMC AC-ICAM cohort, the CMS3 subset of colon cancers, which possessed the highest prevalence of KRAS mutations, displayed a neutral expression of claudin 4 as a whole and did not show upregulation or suppression compared to the entire cohort (Figure 4). Here, CLDN4 is linked to malignant colon neoplasm.